WallStSmart

Newmont Goldcorp Corp (NEM)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1263% more annual revenue ($309.06B vs $22.67B). NVO leads profitability with a 33.1% profit margin vs 31.2%. NEM appears more attractively valued with a PEG of 2.78. NEM earns a higher WallStSmart Score of 65/100 (B-).

NEM

Strong Buy

65

out of 100

Grade: B-

Growth: 6.7Profit: 9.0Value: 4.7Quality: 8.0
Piotroski: 6/9Altman Z: 2.04

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NEMSignificantly Overvalued (-184.1%)

Margin of Safety

-184.1%

Fair Value

$43.86

Current Price

$101.52

$57.66 premium

UndervaluedFair: $43.86Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NEM6 strengths · Avg: 9.3/10
Profit MarginProfitability
31.2%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
58.1%10/10

Strong operational efficiency at 58.1%

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$108.06B9/10

Large-cap with strong market position

Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

NEM2 concerns · Avg: 2.0/10
PEG RatioValuation
2.782/10

Expensive relative to growth rate

EPS GrowthGrowth
-4.6%2/10

Earnings declined 4.6%

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : NEM

The strongest argument for NEM centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 31.2% and operating margin at 58.1%. Revenue growth of 20.6% demonstrates continued momentum.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : NEM

The primary concerns for NEM are PEG Ratio, EPS Growth.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

NEM profiles as a growth stock while NVO is a declining play — different risk/reward profiles.

NEM carries more volatility with a beta of 0.39 — expect wider price swings.

NEM is growing revenue faster at 20.6% — sustainability is the question.

NEM generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

NEM scores higher overall (65/100 vs 55/100), backed by strong 31.2% margins and 20.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Newmont Goldcorp Corp

BASIC MATERIALS · GOLD · USA

Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.

Visit Website →

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?